---
document_datetime: 2023-11-30 11:45:03
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zynrelef-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zynrelef-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.6823247
conversion_datetime: 2025-12-20 08:10:28.847786
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                               | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|---------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10880 /202303  | Periodic Safety Update EU Single assessment - bupivacaine/meloxicam | 26/10/2023                                  | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                      |
| PSUSA/10880 /202209  | Periodic Safety Update EU Single assessment - bupivacaine/meloxicam | 26/04/2023                                  | 23/06/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

ZYNRELEF Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | PSUSA/10880/202209.               |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0011             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/04/2023 | 23/06/2023 | SmPC and PL |                                   |
| II/0009/G           | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation product | 12/01/2023 | n/a no     | longer      | authorised                        |
| PSUSA/10880 /202203 | Periodic Safety Update EU Single assessment - bupivacaine/meloxicam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/10/2022 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0006/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/06/2022 | 23/06/2023 | SmPC        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|-----------------------------------|
| IA/0007/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place product | 03/06/2022 | n/a no | longer authorised                 |
| PSUSA/10880 /202109 | Periodic Safety Update EU Single assessment - bupivacaine/meloxicam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/04/2022 | n/a    | PRAC Recommendation - maintenance |
| IB/0005             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 03/03/2022 | n/a    |                                   |
| IB/0002/G           | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/01/2022 | n/a    |                                   |

<div style=\"page-break-after: always\"></div>

|         | Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure   |            |     |                                             |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------|
| IB/0004 | - Change in container closure system of the                                                                                               | 05/01/2022 | n/a | B.II.e.z Finished Product - Other variation |
| /202103 | Periodic Safety Update EU Single assessment - bupivacaine/meloxicam                                                                       | 28/10/2021 | n/a | PSUSA/10880                                 |

<!-- image -->